Center for Addiction Medicine

Publication Alert: New Subgroup Analysis for the EAGLES Trial

Psychiatric Services recently published results from a post hoc analysis of CAM Director Dr. Eden Evins’s EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study) trial showing the efficacy of Varenicline in smokers with schizophrenia.

The analysis found that Varenicline was more effective than placebo, Bupropion, or nicotine patch for smokers with schizophrenia. Additionally the odds of end-of-treatment abstinence among those with schizophrenia was sixfold higher with Varenicline compared to placebo, and more than twofold higher with Varenicline compared to Bupropion or Nicotine Replacement Therapy (NRT).

The study used a sample of about 8000 smokers. Of the 8,000, about 4000 had a psychiatric illness, and 400 had a psychotic disorder.


For further information, please access the article here: